# Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A

> **NCT07444762** · PHASE3 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 184 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Dyslipidemia

## Interventions

- **DRUG:** DW5421A
- **DRUG:** DW5421B Placebo
- **DRUG:** DW5421B

## Key facts

- **NCT ID:** NCT07444762
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-21
- **Primary completion:** 2025-10-21
- **Final completion:** 2025-10-21
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444762, "Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07444762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*